As a tenure-track Assistant Professor at UTEP, I have a strong background in cancer immunology and pharmaceutical sciences. My research focuses on drug discovery and biomarker identification for drug-resistant cancers.

• UTEP On-Campus Student Internship Awards (2024-2025) - The University of Texas at El Paso (08/06/2024)
• P3 Teacher of the Year, The School of Pharmacy at the University of Texas at El Paso, - The School of Pharmacy at the University of Texas at El Paso (07/01/2023)
• The American Association of Colleges of Pharmacy (AACP) Teacher of the Year - The American Association of Colleges of Pharmacy (07/01/2023)
• The Lizanell and Colbert Coldwell Foundation Research Grant - The Lizanell and Colbert Coldwell Foundation (05/01/2023)
• NATIONAL EYE INSTITUTE (FED) SURE R16 Grant - NIH - NATIONAL EYE INSTITUTE (09/01/2022)
• UTEP On-Campus Student Internship Awards (2022 -2023) - The University of Texas at El Paso (08/01/2022)
• DOD Idea Award in Cancer Research (US Army Medical Research & Material CMD) - DOD (US Army Medical Research & Material CMD) (12/01/2020)
• Top 35 Abstracts, 5th Annual IMMUNO-ONCOLOGY Young Investigators’ Forum - IMMUNO-ONCOLOGY Young Investigators’ Forum (01/01/2019-12/31/2019)
• AACR‐Millennium Scholar-in-Training Award - American Association for Cancer Research (01/01/2013-12/31/2013)
• Trainee Excellence Award - The University of Texas MD Anderson Cancer Center (01/01/2012-12/31/2012)
• AACR-OSI Pharmaceutical Scholar-in-Training Award - American Association for Cancer Research (01/01/2007-12/31/2007)

• Clinical Research, The Society of Clinical Research Associates (SOCRA) (2017)
• Postdoctoral Fellow, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (2014)
• Ph D in Pharmaceutical Science, University of Arizona (2008)
• MS in Pharmacognosy & Microbial-Biochemical Medicine, Peking Union Medical College (2002)
• B.Pharm. in Microbial-Biochemical Medicine (Micropharmaceutics), Shenyang Pharmaceutical Univer (1997)

• Targeting IRS-1/2 in uveal melanoma inhibits in vitro cell growth, survival and migration, and in vivo tumor growth Cancers (Basel) 14(24) (2022), Chandrani Chattopadhyay, Rajat Bhattacharya, Jason Roszik, Fatima Khan, Gabrielle A. Wells, Hugo Villanueva, Yong Qin, Rishav Bhattacharya, Sapna Patel, Elizabeth . Grimm.
• Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. European Journal of Medicinal Chemistry 230 (2022), Huiqiang Wei , Wenfeng Gou, Jun Gao, Hongxin Ning, Yang Song, Deguan Li, Yong Qin, Wenbin Hou, Yiliang Li.
• Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. Cancers 13 13 (2021), A Ballhausen, E Urias, S K. Gruschkus, M Williams, M S. Glover, Yong Qin, D S. Gombos, S P. Patel.
• iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in oncology 11 (2021), Z Ding, D Ogata, J Roszik, Yong Qin, S H. Kim, M T. Tetzlaff, A J. Lazar, M A. Davies, S Ekmekcioglu, E A. Grimm.
• Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. Journal for immunotherapy of cancer 8 2 (2020), Yong Qin, K Bollin, M P. de Macedo, F Carapeto, K B. Kim, J Roszik, K M. Wani, A Reuben, S T. Reddy, M D. Williams, M T. Tetzlaff, W L. Wang, D S. Gombos, B Esmaeli, A J. Lazar, P Hwu, S P. Patel.

• Molecular and Immune Profiling of Hispanic Gastrointestinal Cancer Disparities (2024), Volume Bethesda, MD, USA, Yong Qin.
• Development of a novel pan-chemokine receptor inhibitor as therapeutic for breast cancer (2023), Volume Orlando, Florida, Yong Qin.
• S-nitrosylation of p53 in melanoma alters p53-DNA binding and downstream gene expression (2023), Volume Orlando, Florida, Jordan Winfield, Yong Qin.
• Immune Profile and Immunosuppresive Mechanism of Uveal Melanoma (2022), Volume El Paso, Texas, Yong Qin.
• Nitrosative Stress-driven S-nitrosylation of Key Molecules in Inflammatory Cancers (2021), Volume Seoul, Korea, Yong Qin.

• ON-CAMPUS INTERNSHIP PROGRAM Award
• Eno1, a key modulator and drug target for the tumor microenvironment of cervical cancer
• Novel PHD2/HDACs hybrid inhibitors as therapeutics for advanced cervical cancer
• Development of novel therapeutics to overcome abemaciclib resistance in various cancers
• SOCS1 AS A CRUCIAL REGULATOR FOR RESISTANT UVEAL MELANOMA RESPONSE TO IMMUNOTHERAPY
• Molecular and immune profiling of Hispanic gastrointestinal cancer disparities
• TARGETING A STRESS-DERIVED IMMUNOSUPPRESSIVE ADENOSINE PATHWAY IN TUMORS RESISTANT TO CHECKPOINT INHIBITORS